Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
COGT 
Cogent Biosciences Inc (COGT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: COGT (3-star) is a STRONG-BUY. BUY since 14 days. Simulated Profits (18.97%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $47.18
1 Year Target Price $47.18
| 5 | Strong Buy |
| 4 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 44.34% | Avg. Invested days 37 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.17B USD | Price to earnings Ratio - | 1Y Target Price 47.18 |
Price to earnings Ratio - | 1Y Target Price 47.18 | ||
Volume (30-day avg) 12 | Beta 0.64 | 52 Weeks Range 3.72 - 41.27 | Updated Date 12/1/2025 |
52 Weeks Range 3.72 - 41.27 | Updated Date 12/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-17 | When - | Estimate -0.5229 | Actual -0.5 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -47.47% | Return on Equity (TTM) -95.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5951577703 | Price to Sales(TTM) 1320.63 |
Enterprise Value 5951577703 | Price to Sales(TTM) 1320.63 | ||
Enterprise Value to Revenue 925.41 | Enterprise Value to EBITDA -3.89 | Shares Outstanding 153505562 | Shares Floating 109093105 |
Shares Outstanding 153505562 | Shares Floating 109093105 | ||
Percent Insiders 0.03 | Percent Institutions 92.16 |
Upturn AI SWOT
Cogent Biosciences Inc
Company Overview
History and Background
Cogent Biosciences, Inc. (formerly Unum Therapeutics) is a biotechnology company focused on developing precision therapies for genetically defined diseases. Founded in 2014 (originally as Unum Therapeutics) and has transitioned its focus to kinase inhibitor programs. The company underwent a name change in 2020 to reflect its new strategy.
Core Business Areas
- Precision Oncology: Developing selective kinase inhibitors to treat cancers driven by specific genetic mutations.
Leadership and Structure
The leadership team consists of a CEO, CFO, CMO, and other key executives overseeing research, development, and commercial strategy. The company has a typical biotechnology structure with departments focused on research, clinical development, regulatory affairs, and business operations.
Top Products and Market Share
Key Offerings
- Bezevertinib (CGT-9486): A selective tyrosine kinase inhibitor designed to potently and selectively inhibit mutant KIT D816V. Being developed for Systemic Mastocytosis (SM). Market share is currently 0% as it's in clinical development. Competitors include Blueprint Medicines' AYVAKIT (avapritinib) and Novartis' Gleevec (imatinib) and other therapies being researched.
Market Dynamics
Industry Overview
The industry is characterized by intense competition, high R&D costs, stringent regulatory requirements, and a growing focus on precision medicine and targeted therapies.
Positioning
Cogent Biosciences is positioned as a company specializing in precision therapies for genetically defined diseases, particularly focusing on kinase inhibitors. Their competitive advantage lies in the selectivity of their lead candidate and a focus on unmet medical needs.
Total Addressable Market (TAM)
The TAM for systemic mastocytosis and other genetically driven cancers is significant and growing, estimated to be several billion dollars. Cogent's positioning is to capture a significant portion of this TAM with effective and targeted therapies. Market varies based on the indication, regulatory approval and commercial execution.
Upturn SWOT Analysis
Strengths
- Selective Kinase Inhibitor Technology
- Strong Focus on Precision Medicine
- Experienced Management Team
- Clinical-Stage Pipeline
Weaknesses
- Limited Revenue Stream (pre-commercialization)
- Reliance on Clinical Trial Success
- High Cash Burn Rate
- Competition from Established Players
Opportunities
- Successful Clinical Trial Outcomes
- Expansion into New Indications
- Potential for Strategic Partnerships
- Favorable Regulatory Environment for Orphan Drugs
Threats
- Clinical Trial Failures
- Regulatory Hurdles
- Competition from Novel Therapies
- Patent Expiration
Competitors and Market Share
Key Competitors
- BLPR
- NVS
- MRTX
Competitive Landscape
Cogent Biosciences competes with established pharmaceutical companies and other biotech firms in the precision oncology space. Differentiation is based on the selectivity of their kinase inhibitors and their focus on specific genetic mutations.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been driven by pipeline advancement and funding rounds.
Future Projections: Future growth is dependent on Bezevertinib's approval. Analyst estimates vary widely based on assumptions related to clinical trial success and market penetration.
Recent Initiatives: Advancement of Bezevertinib through Phase 2 trials for Systemic Mastocytosis and ongoing research into additional kinase inhibitors.
Summary
Cogent Biosciences is a clinical-stage biotechnology company focused on precision oncology. The company's strength lies in its selective kinase inhibitor technology. However, it is susceptible to clinical trial failures. Successful development and commercialization of Bezevertinib is critical for long-term success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q), Company Website, Press Releases, Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be made based on your own research and consultation with a financial advisor. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cogent Biosciences Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2018-03-29 | President, CEO & Director Mr. Andrew R. Robbins M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 205 | Website https://www.cogentbio.com |
Full time employees 205 | Website https://www.cogentbio.com | ||
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.